Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
578 articles with Regeneron Pharmaceuticals, Inc.
Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration.
Shares of Regeneron are down following reports of increased observations of known side effects from blockbuster drug Eylea were reported by providing doctors.
The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable.
Ms. McCourt has more than two decades of broad experience in biopharmaceutical management with an emphasis on commercial strategy and execution.
Regeneron today announced financial results for the fourth quarter and full year 2017 and provided a business update.
Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018
The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Regeneron Announces Approval of DUPIXENT (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron today announced that the MHLW in Japan has granted marketing and manufacturing authorization for DUPIXENT for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies.
1/17/2018Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.
Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource With UK Biobank
Regeneron along with new collaborators AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer, today announced the formation of a major 'pre-competitive' consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource.
The two companies struck the deal in 2015.
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Regeneron filed the complaint against Merus alleging that it infringed one or more claims in the '018 patent in 2014.
12/20/2017We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards.
Regeneron and ISA Pharma today announced a clinical collaboration to advance ISA101 in combination with cemiplimaba, a PD-1 antibody.
Regeneron shares have made little headway since the disappointing launch of Praluent in 2015.
In a separate release today the companies also shared positive topline results for PD-1 antibody cemiplimab in advanced CSCC.
The positive results are spurring the companies to begin seeking approval for the checkpoint inhibitor.
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients With Wet AMD
Under the PDUFA, the goal for a standard review of an sBLA is ten months from submission for a target action date of August 11, 2018.
Regeneron and Decibel scientists will be working together, shoulder to shoulder, on project teams beginning at the earliest stages of research.
Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.